Evidence map›Paper›PMID 30015387›Full record

ArticleJournal of cellular biochemistry2018

Computational and biochemical studies of isothiocyanates as inhibitors of proteasomal cysteine deubiquitinases in human cancer cells.

Zainab Sabry Othman Ahmed, Xin Li, Feng Li, Hassan Ali Cheaito, Kush Patel, El-Sayed Mohammed Mosallam, Gehad Abd El-Fattah Hassan Elbargeesy, Q Ping Dou

Abstract read
In one paragraph

Article in Journal of cellular biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Zainab Sabry Othman AhmedBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
Xin LiBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
Feng LiBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
Hassan Ali CheaitoBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
Kush PatelBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
El-Sayed Mohammed MosallamDepartment of Cytology and Histology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Gehad Abd El-Fattah Hassan ElbargeesyDepartment of Cytology and Histology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Q Ping DouBarbara Ann Karmanos Cancer Institute, Departments of Oncology, Pharmacology, and Pathology, School of Medicine, Wayne State University, Detroit, Michigan.
The Barbara Ann Karmanos Cancer Institute · USWayne State University · USCairo University · EG

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
(PQA1) Regulation of Metformin Response by Breast Cancer Associated Gene 2 (BCA2)R21CA184788 · NCI · WAYNE STATE UNIVERSITY · PI DOU, QING PING · 2014 to 2015
$364k
NCI NIH HHS P30 CA022453NCI NIH HHS R21 CA184788
6 · The paper itself

Abstract

Isothiocyanates (ITCs) are natural chemoprotective products found abundantly in cruciferous vegetables. However, the cancer-relevant targets and molecular mechanisms of ITCs remain unclear. We hypothesize that ITCs, as electrophiles, can interact with the catalytic triads (CYS, HIS, and ASP) of the proteasomal cysteine deubiquitinases USP14 and UCHL5, ultimately inhibiting their activities. In the current study, we exploited this possibility by performing both computational docking and biochemical validation assays using human breast and prostate cancer cell models. Docking results suggest that benzyl isothiocyanate, phenethyl isothiocyanate, and DL-sulforaphane are more potent inhibitors of UCHL5 than USP14, and these ITCs could interact with the catalytic triads of UCHL5 and USP14. Indeed, ubiquitin vinyl sulfone assay confirmed the inhibitory activity of each ITC on the ubiquitin-binding activity of UCHL5 and USP14. We also found that inhibition of USP-14 and UCHL5 activities by the ITCs caused increased levels of USP14 and UCHL5 proteins, but not the third 19S-deubiquitinating enzyme (DUB), POH1/RPN11, suggesting feedback loop activation and further supporting that ITCs are inhibitors of proteasomal cysteine DUBs. Associated with DUB inhibition by ITCs, ubiquitinated proteins were significantly increased, accompanied with induction of apoptosis, inhibition of proliferation and suppression of cell invasion. Our findings of ITCs as proteasomal cysteine DUB inhibitors should provide insightful information for designing, discovering and developing potent, specific 19S-DUB inhibitors for cancer therapies.

Indexed as

Cell Line, TumorCell SurvivalComputational BiologyDeubiquitinating EnzymesHumansIsothiocyanatesMaleProteasome Endopeptidase ComplexTrans-ActivatorsUbiquitin ThiolesteraseDeubiquitinating EnzymesIsothiocyanatesProteasome Endopeptidase ComplexPSMD14 protein, humanTrans-ActivatorsUbiquitin ThiolesteraseUCHL5 protein, humanUSP14 protein, humanbenzyl isothiocyanate (BITC)drug discoveryphenethyl isothiocyanate (PEITC)sulforaphane (SFN)ubiquitin-proteasome systemUCHL5USP14

Identifiers

PMID30015387
PMCPMC6195458
OpenAlexW2883537866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.